ArticlePloS one2025
Relationships between hemoglobin levels at admission and adverse maternal and perinatal outcomes in patients with preeclampsia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond deficiency: The emerging health risks of excess iron.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMaternal hemoglobin is very important for maternal and perinatal outcomes. Due to the pathophysiological changes in patients with preeclampsia, the influence of hemoglobin on pregnancy outcomes may differ from that in normal pregnant women. Therefore, this retrospective study aimed to evaluate the relationships between maternal hemoglobin levels and adverse maternal and perinatal outcomes in patients with preeclampsia.
methodsAll clinical data were retrospectively collected from the medical records of a tertiary obstetrics and gynecology hospital in China. This study evaluated the incidence of adverse maternal and perinatal outcomes in patients with preeclampsia with different hemoglobin levels at admission. The odds ratios and 95% confidence intervals for adverse pregnancy outcomes in patients with preeclampsia with anemia and high hemoglobin levels were estimated, with the normal hemoglobin level serving as the control.
resultsA total of 1,715 patients with preeclampsia with singleton pregnancies were included in this retrospective study. Compared with patients with preeclampsia with normal hemoglobin levels, patients with anemia at admission had a greater risk for postpartum hemorrhage (OR: 3.800; 95% CI: 1.677-8.610) and cardiac dysfunction (OR: 2.860; 95% CI: 0.979-8.356). Moreover, patients with high hemoglobin levels at admission had increased risks of HELLP syndrome (OR: 2.503; 95% CI: 1.198-5.229), SGA (OR: 1.343; 95% CI: 0.997-1.808), neonatal asphyxia (OR: 2.046; 95% CI: 1.107-3.784) and NICU admission (OR: 1.359; 95% CI: 1.060-1.742). However, not all abnormal hemoglobin levels were associated with an increased risk of adverse pregnancy outcomes. Patients with preeclampsia with anemia had a lower risk of adverse perinatal outcomes, including SGA (OR: 0.731; 95% CI: 0.517-1.032) and NICU admission (OR: 0.737; 95% CI: 0.567-0.960).
conclusionThis study revealed that both anemia and high hemoglobin levels at admission were related to adverse maternal and perinatal outcomes in patients with preeclampsia. The effects of hemoglobin on adverse maternal and perinatal outcomes in patients with preeclampsia may differ from those in normal pregnant women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.